Pediatric inflammatory bowel disease

World Journal of Gastroenterology

Volumn 12, Issue 20, 2006, Pages 3204-3212

  Diefenbach, Karen A ^a   Breuer, Christopher K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Crohn's disease; Inflammatory bowel; Pediatric; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; AZASAN; AZATHIOPRINE; AZULFADINE; BALSALAZIDE; BUDESONIDE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; HLA A ANTIGEN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OLSALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ACNE; AGE DISTRIBUTION; ANOREXIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CHILD; CHILL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DIAGNOSTIC IMAGING; DIARRHEA; DRUG ERUPTION; DYSPNEA; ENTERITIS; FATIGUE; FEVER; FLUSHING; GASTROINTESTINAL ENDOSCOPY; GINGIVA HYPERPLASIA; GROUPS BY AGE; HEADACHE; HEPATITIS; HIGH RISK POPULATION; HIRSUTISM; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; INFECTION; JOINT STIFFNESS; LABORATORY DIAGNOSIS; LEUKOPENIA; LUPUS LIKE SYNDROME; MALAISE; MOUTH ULCER; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PATHOGENESIS; POPULATION DISTRIBUTION; REVIEW; RISK FACTOR; SEPSIS; SIDE EFFECT; THORAX PAIN; TUBERCULOSIS; ULCERATIVE COLITIS; URTICARIA; WEIGHT GAIN;

EID: 33745072994     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i20.3204     Document Type: Review

References (50)

1. Murch SH, Baldassano R, Buller H, Chin S, Griffiths AM, Hildebrand H, Jasinsky C, Kong T, Moore D, Orsi M. Inflammatory bowel disease: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39 Suppl 2: S647-654
2. Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am 2003; 32: 967-995, viii
3. Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology 2004; 126: 1550-1560
4. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999; 28: 445-458
5. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 255-281, vii
6. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205
7. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ,Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122: 867-874
8. Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr 2005; 40: 262-272
9. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123: 679-688
10. Nishiwaki T, Ina K, Goto H, Watanabe O, Tsuzuki T, Furuta R, Ando T, Hibi K, Kusugami K. Possible involvement of the interleukin-15 and interleukin-15 receptor system in a heightened state of lamina propria B cell activation and differentiation in patients with inflammatory bowel disease. J Gastroenterol 2005; 40: 128-136
11. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115: 822-829
12. Fish D, Kugathasan S. Inflammatory bowel disease. Adolesc Med Clin 2004; 15: 67-90, ix
13. Raj V, Lichtenstein DR. Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 491-513
14. Seidman EG. Recent advances in the diagnosis and treatment of pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2000; 2: 248-252
15. Scotiniotis I, Rubesin SE, Ginsberg GG. Imaging modalities in inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 391-421, ix
16. Wiarda BM, Kuipers EJ, Houdijk LP, Tuynman HA. MR enteroclysis: imaging technique of choice in diagnosis of small bowel diseases. Dig Dis Sci 2005; 50: 1036-1040
17. Chong AK, Taylor A, Miller A, Hennessy O, Connell W, Desmond P. Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease. Gastrointest Endosc 2005; 61: 255-261
18. Antonioli DA. Pediatric inflammatory bowel disease. Pediatr Dev Pathol 2005; 8: 2-19
19. Friedman S. General principles of medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 2004; 33:191-208, viii
20. Hanauer SB, Korelitz BL, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723-729
21. Becker JM. Surgical therapy for ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1999; 28: 371-390, viii-ix
22. Schraut WH. The surgical management of Crohn's disease. Gastroenterol Clin North Am 2002; 31: 255-263
23. Tekkis PP, Heriot AG, Smith O, Smith JJ, Windsor AC, Nicholls RJ. Long-term outcomes of restorative proctocolectomy for Crohn's disease and indeterminate colitis. Colorectal Dis 2005; 7: 218-223
24. Baldassano RN, Han PD, Jeshion WC, Berlin JA, Piccoli DA, Lautenbach E, Mick R, Lichtenstein GR. Pediatric Crohn's disease: risk factors for postoperative recurrence. Am J Gastroenterol 2001; 96: 2169-2176
25. Wewer V, Hesselfeldt P, Qvist N, Husby S, Paerregaard A. J-pouch ileoanal anastomosis in children and adolescents with ulcerative colitis: functional outcome, satisfaction and impact on social life. J Pediatr Gastroenterol Nutr 2005; 40: 189-193
26. Ikeuchi H, Nakano H, Uchino M, Nakamura M, Noda M, Yanagi H, Yamamura T. Safety of one-stage restorative proctocolectomy for ulcerative colitis. Dis Colon Rectum 2005; 48: 1550-1555
27. Blumberg D, Beck DE. Surgery for ulcerative colitis. Gastroenterol Clin North Am 2002; 31: 219-235
28. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47: 487-496
29. Day AS, Whitten KE, Bohane TD. Childhood inflammatory bowel disease: parental concerns and expectations. World J Gastroenterol 2005; 11: 1028-1030
30. De Boer M, Grootenhuis M, Derkx B, Last B. Health-related quality of life and psychosocial functioning of adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 400-406
31. Sainsbury A, Heatley RV. Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 21: 499-508
32. Cuffari C, Darbari A. Inflammatory bowel disease in the pediatric and adolescent patient. Gastroenterol Clin North Am 2002; 31: 275-291
33. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250
34. Silva MA, Menezes J, Deslandres C, Seidman EG. Anti-inflammatory role of interleukin-15 in Crohn's disease. Inflamm Bowel Dis 2005; 11: 219-230
35. Zankel E, Rogler G, Andus T, Reng CM, Scholmerich J, Timmer A. Crohn's disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. Eur J Gastroenterol Hepatol 2005; 17: 395-401
36. Levine A, Shamir R, Wine E, Weiss B, Karban A, Shaoul RR, Reif SS, Yakir B, Friedlander M, Kaniel Y, Leshinsky-Silver E. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease. Am J Gastroenterol 2005; 100: 1598-1604
37. Mackner LM, Crandall WV. Long-term psychosocial outcomes reported by children and adolescents with inflammatory bowel disease. Am J Gastroenterol 2005; 100: 1386-1392
38. Lewis JD, Deren JJ, Lichtenstein GR. Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 459-477, x
39. Han PD, Burke A, Baldassano RN, Rombeau JL, Lichtenstein GR. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 423-443, ix
40. Sharan R, Schoen RE. Cancer in inflammatory bowel disease. An evidence-based analysis and guide for physicians and patients. Gastroenterol Clin North Am 2002; 31: 237-254
41. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005; 11: 213-218
42. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104-111
43. Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98: 833-838
44. Markowitz J, Grancher K, Kohn N, Daum F. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am J Gastroenterol 2002; 97: 928-932
45. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-1608
46. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902
47. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260
48. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713
49. Chen QK, Yuan SZ, Wen ZF, Zhong YQ, Li CJ, Wu HS, Mai CR, Xie PY, Lu YM, Yu ZL. Characteristics and therapeutic efficacy of sulfasalazine in patients with mildly and moderately active ulcerative colitis. World J Gastroenterol 2005; 11: 2462-2466
50. Lomer MC, Grainger SL, Ede R, Catterall AP, Greenfield SM, Cowan RE, Vicary FR, Jenkins AP, Fidler H, Harvey RS, Ellis R, McNair A, Ainley CC, Thompson RP, Powell JJ. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2005; 17: 377-384